Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hybridoma Technology01:31

Hybridoma Technology

17.0K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
17.0K
Transcytosis of IgG01:15

Transcytosis of IgG

3.9K
Transcytosis is the process in which molecules are internalized by endocytosis, transported across the cell, and released through exocytosis from the opposite end of the cell. Molecules such as insulin, immunoglobulins, and certain nutrients are transferred through the recycling endosomes by recycling and transcytosis.
IgG molecules from a mother undergo transcytosis starting around 13 weeks of gestation. The amount of IgG transferred and entering the fetal blood circulation increases with...
3.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pivotal Clinical Trials in C3 Glomerulopathy: answers and remaining uncertainties.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association·2026
Same author

Kidney failure in patients with ANCA-associated vasculitis: A systematic review of outcomes.

Autoimmunity reviews·2026
Same author

Cardiovascular disease and risk management in patients with nephrotic syndrome.

Kidney research and clinical practice·2026
Same author

The NDT and MARKUS@HOMe Partnership.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association·2026
Same author

Advances in the diagnosis and detection of chronic kidney disease.

Lancet (London, England)·2026
Same author

Uromodulin and Tryptophan Metabolite Clearance in Hemodialyzed Patients.

Journal of clinical medicine·2026
Same journal

Using Preoperative Therapeutic Plasma Exchange in Lupus Anticoagulant Hypoprothrombinemia Syndrome to Achieve Hemostatic Factor II Activity: A Case Report.

Journal of clinical apheresis·2026
Same journal

Calcium and Other Electrolyte Management in Patients Undergoing Leukocytapheresis Collections: Review and Recommendations From the American Society for Apheresis Clinical Applications Committee.

Journal of clinical apheresis·2026
Same journal

The Role of Therapeutic Apheresis in the Management of Rheumatoid Arthritis A Systematic Review and Meta-Analysis.

Journal of clinical apheresis·2026
Same journal

Thrombocytapheresis as a Bridge Intervention in JAK2-Mutant Myeloproliferative Neoplasm Complicated by Acquired von Willebrand Disease: A Case Report.

Journal of clinical apheresis·2026
Same journal

Plerixafor Plus G-CSF Versus Etoposide Combined With Cyclophosphamide and G-CSF for Autologous Stem Cell Mobilization in Multiple Myeloma in the Era of Novel Agents: A Single Center Observational Propensity Score-Matched Cohort Study.

Journal of clinical apheresis·2026
Same journal

Beyond the Centrifuge: Is FcRn Inhibition Ready to Replace Apheresis in Treatment of Guillain-Barré Syndrome?

Journal of clinical apheresis·2026
See all related articles

Related Experiment Video

Updated: Dec 26, 2025

Assessment of Antibody-based Drugs Effects on Murine Bone Marrow and Peritoneal Macrophage Activation
10:35

Assessment of Antibody-based Drugs Effects on Murine Bone Marrow and Peritoneal Macrophage Activation

Published on: December 26, 2017

8.6K

Lessons learned from immunoadsorption for hyperviscosity in IgM multiple myeloma-A case report.

Philipp Gauckler1, Johannes Leierer1, Florian Kocher2

  • 1Department of Internal Medicine IV (Nephrology and Hypertension), Medical University Innsbruck, Innsbruck, Austria.

Journal of Clinical Apheresis
|March 7, 2020
PubMed
Summary
This summary is machine-generated.

Immunoadsorption significantly reduced pembrolizumab levels in a patient with IgM multiple myeloma and hyperviscosity syndrome. This extracorporeal therapy necessitates re-dosing of monoclonal antibodies for sustained efficacy.

Keywords:
drug levelsimmunoglobulinmonoclonal antibodypembrolizumabtherapeutic apheresis

More Related Videos

Antibody Binding Specificity for Kappa (Vκ) Light Chain-containing Human (IgM) Antibodies: Polysialic Acid (PSA) Attached to NCAM as a Case Study
11:10

Antibody Binding Specificity for Kappa (Vκ) Light Chain-containing Human (IgM) Antibodies: Polysialic Acid (PSA) Attached to NCAM as a Case Study

Published on: June 29, 2016

14.4K
Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
09:02

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Published on: November 26, 2018

22.2K

Related Experiment Videos

Last Updated: Dec 26, 2025

Assessment of Antibody-based Drugs Effects on Murine Bone Marrow and Peritoneal Macrophage Activation
10:35

Assessment of Antibody-based Drugs Effects on Murine Bone Marrow and Peritoneal Macrophage Activation

Published on: December 26, 2017

8.6K
Antibody Binding Specificity for Kappa (Vκ) Light Chain-containing Human (IgM) Antibodies: Polysialic Acid (PSA) Attached to NCAM as a Case Study
11:10

Antibody Binding Specificity for Kappa (Vκ) Light Chain-containing Human (IgM) Antibodies: Polysialic Acid (PSA) Attached to NCAM as a Case Study

Published on: June 29, 2016

14.4K
Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
09:02

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Published on: November 26, 2018

22.2K

Area of Science:

  • Hematology
  • Immunology
  • Nephrology

Background:

  • A patient with relapsed IgM multiple myeloma (MM) presented with hyperviscosity syndrome and visual impairment.
  • Treatment included an experimental protocol with pembrolizumab, pomalidomide, and dexamethasone.

Observation:

  • Immunoadsorption (IA) was employed using columns with single domain camelid antibody fragments to reduce free kappa light chains (fκLC) and IgM.
  • Pembrolizumab (humanized IgG4 kappa anti-PD1 antibody) levels were measured before and after IA sessions.

Findings:

  • IA resulted in a 98.1% reduction in pembrolizumab levels after five sessions.
  • Serum IgG elimination kinetics were comparable to pembrolizumab, while fκLC and IgM reduction was less substantial.
  • Broad-spectrum IA showed moderate effectiveness for IgM MM hyperviscosity compared to plasma exchange.

Implications:

  • Extracorporeal therapies like IA efficiently reduce monoclonal antibodies, requiring re-dosing for therapeutic efficacy.
  • IA may be a strategy to manage immune-related adverse events by eliminating monoclonal antibodies.
  • Monitoring serum IgG levels can help track monoclonal antibody drug levels during IA therapy.